NYSE:GKOSMedical Equipment
Assessing Glaukos (GKOS) Valuation After Strong Revenue Update And Epioxa FDA Approval
Why Glaukos Is Back on Investors’ Radar
Glaukos (GKOS) has attracted fresh attention after issuing preliminary fourth quarter and full year 2025 revenue figures, reaffirming its 2026 sales outlook, and securing FDA approval for its Epioxa corneal health product.
See our latest analysis for Glaukos.
After a sharp 58.5% 90 day share price return and a 3.2% 30 day share price gain, Glaukos has pulled back 4.7% over the last day. Its 1 year total shareholder return of a 25.1% loss contrasts with...